Article
Oncology
Marie-Christina Jahreiss, Wilma D. Heemsbergen, Bo van Santvoort, Mischa Hoogeman, Maarten Dirkx, Floris J. Pos, Tomas Janssen, Andre Dekker, Ben Vanneste, Andre Minken, Carel Hoekstra, Robert J. Smeenk, Inge M. van Oort, Chris H. Bangma, Luca Incrocci, Katja K. H. Aben
Summary: Prostate cancer survivors treated with EBRT have an increased risk of developing solid second primary cancers (SPC), especially in the pelvic area. The risk of pelvic SPC is consistently higher in all EBRT eras, while non-pelvic SPC risks are particularly elevated in the advanced RT (AdvRT) era. Comparison to the prostatectomy cohort showed higher risks of both pelvic and non-pelvic SPC in the EBRT group, with the highest risks observed in the AdvRT period.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Guoqiao Zheng, Jan Sundquist, Kristina Sundquist, Jianguang Ji
Summary: Women with a family history of BCa-2 have a similar overall BC risk as those with a family history of BCa-1, with the risk varying according to the site of first primary cancer diagnosed in FDR before BCa-2.
Article
Endocrinology & Metabolism
Mijin Kim, Hyereen Kim, Sojeong Park, Jaeeun Joo, In Ju Kim, Bo Hyun Kim
Summary: Thyroid cancer survivors are at a higher risk of developing second primary malignancies (SPMs), especially myeloid leukemia and various solid cancer sites. Frequent diagnostic radiation exposure and high-dose radioactive iodine (RAI) therapy are independent risk factors for SPMs following thyroid cancer.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Oncology
Chengshi Wang, Kejia Hu, Chuanxu Luo, Lei Deng, Katja Fall, Rulla M. Tamimi, Unnur A. Valdimarsdottir, Fang Fang, Donghao Lu
Summary: The study findings suggest that cancer survivors who develop breast cancer as a second malignancy are at increased risk of cardiovascular mortality, especially pronounced in individuals aged 30-49 years.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Fei Chen, Sungshim L. Park, Lynne R. Wilkens, Peggy Wan, Steven N. Hart, Chunling Hu, Siddhartha Yadav, Fergus J. Couch, David V. Conti, Adam J. de Smith, Christopher A. Haiman
Summary: This multiethnic study found that germline pathogenic variants in BRCA1, BRCA2, and ERCC2 are associated with the development of second primary cancer in breast cancer survivors, providing biological insights and biomarkers for patient monitoring.
Article
Biochemistry & Molecular Biology
Mohammad Hussein, Lauren Mueller, Peter P. Issa, Muhib Haidari, Lily Trinh, Eman Toraih, Emad Kandil
Summary: Primary cancer survivors have a higher risk of developing second primary thyroid cancer, especially in the first three years after the diagnosis of the primary cancer. The latency period for developing second primary thyroid cancer varies depending on the type of primary cancer, and this information can help clinicians develop appropriate screening and surveillance plans for thyroid cancer.
Article
Oncology
Chengshi Wang, Kejia Hu, Lei Deng, Wei He, Fang Fang, Rulla M. Tamimi, Donghao Lu
Summary: Patients with breast cancer as a second malignancy have worse breast cancer-specific survival compared to those with first primary breast cancer, although the risk elevation is mild. High-risk subgroups based on characteristics of the first malignancy may be considered for active clinical management.
Article
Oncology
Guoqiao Zheng, Jan Sundquist, Kristina Sundquist, Jianguang Ji
Summary: Individuals with a family history of both CRCa-1 and CRCa-2 have a lower risk of CRC compared to individuals with only CRCa-1, which is related to the age of diagnosis of CRC in FDR and family relationships.
Article
Multidisciplinary Sciences
Zhijia Zhang, Fei Liu, Yanlin Qu, Liqian Qiu, Liqun Zhang, Qiao Yang
Summary: The study investigated the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older using the SEER database. It found that younger age, male gender, surgery history, local stage, and first primary malignancy (FPM) site located in the urinary system were related to a higher cumulative incidence of SPM. The median time interval between diagnosis of FPM and SPM was 24.0 months, with the most common SPM site being the digestive system.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Ellinor Lundberg, Pernilla Lagergren, Fredrik Mattsson, Jesper Lagergren
Summary: This study investigated whether the survival of patients cured of esophageal cancer differs from that of the corresponding background population. The study found that there is a decline in relative survival rates among esophageal cancer survivors between 6 and 10 years after surgery, especially in those with a history of squamous cell carcinoma and male patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Heidy N. Medina, Matthew P. Schlumbrecht, Frank J. Penedo, Paulo S. Pinheiro
Summary: The study found that the survival rate of endometrial cancer as a second primary is superior to that of the first primary. However, ECSPs following colorectal cancer may constitute a population of interest for their worse prognosis. Patients who had chemotherapy for a previous breast cancer did not have a higher risk of death compared to those who only received chemotherapy for the first primary endometrial cancer.
Article
Oncology
Cody Ramin, Lene H. S. Veiga, Jacqueline B. Vo, Rochelle E. Curtis, Clara Bodelon, Erin J. Aiello Bowles, Diana S. M. Buist, Sheila Weinmann, Heather Spencer Feigelson, Gretchen L. Gierach, Amy Berrington de Gonzalez
Summary: Breast cancer survivors treated in recent decades have an increased risk of developing second primary cancers. This study found that they had a 70% higher risk of any cancer and a 45% higher risk of non-breast cancer compared to the general population. Enhanced surveillance and efforts to reduce the occurrence of second cancers are needed for breast cancer survivors.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Jiaqin Xu, Chen Huang, Zhenyu Wu, Huilin Xu, Jiong Li, Yuntao Chen, Ce Wang, Jingjing Zhu, Guoyou Qin, Xueying Zheng, Yongfu Yu
Summary: This study aimed to characterize the clinical features of early-stage ovarian cancer survivors with second primary malignancies and provided a prediction tool for personalized risk assessment. The results showed that several factors, including age, race, histologic subtypes of OC, lymph node examination, and radiotherapy, were significantly associated with an elevated risk of developing SPMs. The proposed nomogram demonstrated clinical utility in identifying patients with different risks of SPMs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Jannie Dressler, Sisse H. Njor, Lars N. Jorgensen, Morten Rasmussen
Summary: This study compared the primary treatment strategies between patients diagnosed with screen-detected colorectal cancer (SD-CRC) and non-screen-detected colorectal cancer (NSD-CRC) and found that SD-CRC patients had less invasive surgical treatment and a higher proportion of stage IV patients underwent surgery.
WORLD JOURNAL OF SURGERY
(2023)
Article
Oncology
Fan-Wen Lin, Ming-Hsin Yeh, Cheng-Li Lin, James Cheng-Chung Wei
Summary: There is a special association between breast cancer and second primary lung cancer in Taiwanese women, particularly in younger groups and in those without any comorbidities, which is supposed to increase public awareness.
Article
Oncology
Avonne E. Connor, Maneet Kaur, Kate E. Dibble, Kala Visvanathan, Lorraine T. Dean, Jennifer H. Hayes
Summary: The study revealed that in Maryland, women living in the least privileged census tracts with lower income households and higher proportions of Black residents had a higher hazard of breast cancer mortality. This association varied significantly by race and age, with Black women having a lower hazard compared to White women, and younger women having greater hazards than older women.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Pritesh S. Karia, Parisa Tehranifar, Kala Visvanathan, Jason D. Wright, Jeanine M. Genkinger
Summary: There are significant differences in gynecologic cancer mortality between Asian Americans and non-Hispanic Whites, with heterogeneity among Asian American ethnic groups. Disaggregated analysis of Asian Americans is needed to better understand the burden of gynecologic cancer and identify high-risk groups for cancer prevention efforts.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar
Summary: This study evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay for early assessment of disease progression in women with metastatic breast cancer (MBC). The results showed that high levels of cumulative methylation (CM) were associated with shorter median progression-free survival (PFS) and overall survival (OS) at week 4. The CM levels at week 4 could be used to predict disease progression as early as 3 months after initiating a new treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Antonio C. Wolff, Kala Visvanathan
Summary: Higher cancer mortality was observed among Non-Hispanic Black and Hispanic survivors, while higher cardiovascular mortality was observed among Non-Hispanic Black survivors among women who survive a first breast cancer to develop a second primary cancer.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Kate. E. E. Dibble, Zhengyi Deng, Avonne. E. E. Connor
Summary: This study aimed to determine if there are disparities in survivorship care experiences among older breast cancer survivors based on breast cancer characteristics, race/ethnicity, and socioeconomic factors. The results showed that there were associations between clinical cancer characteristics and survivorship care experiences. The study suggests that these findings can help inform survivorship care providers in treating women diagnosed with more advanced stage and aggressive disease, and further research is needed to evaluate the impact of minority groups and socioeconomic status on survivorship care.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Kate E. Dibble, Zhengyi Deng, Mu Jin, Avonne E. Connor
Summary: This study aimed to investigate racial/ethnic disparities in survivorship care patient experiences among older breast cancer survivors. The results showed that compared to white survivors, black and Asian survivors reported lower scores in getting care quickly, getting needed care, and overall care ratings. The findings varied among Hispanic survivors.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Antonio C. Wolff, Kala Visvanathan
Summary: The UK National Health Service's Predict tool performs well in predicting breast cancer-specific mortality for first breast cancer, but underestimates it for second breast cancer, especially for estrogen receptor-positive breast cancer patients.
JNCI CANCER SPECTRUM
(2023)
Meeting Abstract
Oncology
Kate E. Dibble, Zhengyi Deng, Avonne E. Connor
Meeting Abstract
Oncology
Xinyi Feng, Zhengyi Deng, Michelle McCollough, Betty May, Erica Selznick, Avonne Connor, Deborah K. Armstrong, Kala Visvanathan
Review
Public, Environmental & Occupational Health
Aisha S. Dickerson, Seth Frndak, Irena Gorski-Steiner, Zhengyi Deng, Tara E. Jenson, Ankita Mohan, Jake Kim, Verne Qaanaaq Boerner, Roland J. Thorpe Jr
Summary: The purpose of this review is to discuss the higher incidence of dementia in Black and Hispanic populations and those with less education, and the proposed risk factor of air pollution. Reports on ambient pollution and cognitive decline are examined, and the importance of investigations in marginalized populations is emphasized. Areas for future research are recommended.
CURRENT EPIDEMIOLOGY REPORTS
(2023)
Meeting Abstract
Oncology
Kate E. Dibble, Zhengyi Deng, Avonne E. Connor
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Meeting Abstract
Oncology
Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Kala Visvanathan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
